IMM-H007 improves heart function via reducing cardiac fibrosis

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Molecular Medicine

Background:

• Cardiac dysfunction involves left ventricular (LV) impairment, hypertrophy, and fibrosis.
• AMP-Activated Protein Kinase (AMPK) activation can reduce fibrosis by decreasing transforming growth factor-β1 (TGF-β1) expression.

Purpose of the Study:

• To investigate the potential of IMM-H007, an AMPK activator, in mitigating cardiac dysfunction and fibrosis.
• To elucidate the underlying molecular mechanisms involving the AMPK-TGF-β1 signaling pathway.

Main Methods:

• Utilized an angiotensin II (AngII)-induced cardiac remodeling mouse model.
• Administered IMM-H007 and assessed cardiac function via echocardiography.
• Analyzed cardiac tissue using histological staining, qRT-PCR, and immunoblotting.
• Investigated IMM-H007 effects on primary mouse and human cardiac fibroblasts.

Main Results:

• IMM-H007 significantly improved LV ejection fraction and fractional shortening.
• Reduced AngII-induced cardiac fibroblast activation and collagen production.
• Activated AMPK, decreased TGF-β1 expression, and inhibited Smad2 activation in heart tissue.
• IMM-H007 did not impact AngII-induced cardiac hypertrophy.

Conclusions:

• IMM-H007 ameliorates cardiac fibrosis and improves heart function by activating the AMPK-TGF-β1 pathway.
• Findings suggest IMM-H007 as a potential therapeutic agent for cardiac dysfunction associated with fibrosis.